10x Genomics Q3 revenue $153.6M (+17% YoY), net loss $93.0M; raises FY2023 guidance

10x Genomics, Inc.

2023-Q3 EPS reported -$1.77 revenue$434,748,000

Q3 2023 revenue $153.6M, up 17% YoY; raised FY2023 guidance to $610-625M.
Gross margin fell to 62% from 77% YoY due to product mix from Xenium instrument placements.
Operating loss $94.8M ($40.0M prior year); includes $41.4M in-process R&D and $40.2M stock comp.
Net loss $93.0M vs $41.9M; cash & securities $356.9M as of Sep 30.
Xenium platform driving demand; launched new panel configurations and Beckman Coulter partnership.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

10x Genomics, Inc. reported for the third quarter ended September 30, 2023 results: revenue $153.6 million, net income Net loss was $93.0 million. Guidance raised.

Period: for the third quarter ended September 30, 2023
Revenue: $153.6 million
Net income: Net loss was $93.0 million
Guidance: raised
Result: reported results

Exact text from the filing

Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the third quarter ended September 30, 2023. Recent Highlights • Revenue was $153.6 million for the third quarter, a 17% increase over the corresponding period of 2022, driven by Xenium momentum. • Advanced Xenium gene panel strategy, launching new targeted and custom

View on SEC.gov

Browse all earnings releases →

10x Genomics, Inc. filing history →

Source: SEC EDGAR

accession 0001770787-23-000051

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.